Sharon X. Wen

Array ( [id] => 10946372 [patent_doc_number] => 20140349393 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-27 [patent_title] => 'Fusion Partner for Production of Monoclonal Rabbit Antibodies' [patent_app_type] => utility [patent_app_number] => 14/283093 [patent_app_country] => US [patent_app_date] => 2014-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7472 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14283093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10939353 [patent_doc_number] => 20140342374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'Acute Leukemia And Lymphoblastic Lymphoma-Specific CD43 Epitope and Use Thereof' [patent_app_type] => utility [patent_app_number] => 14/269018 [patent_app_country] => US [patent_app_date] => 2014-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 8165 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14269018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10729604 [patent_doc_number] => 20160075753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-17 [patent_title] => 'MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-eta' [patent_app_type] => utility [patent_app_number] => 14/888313 [patent_app_country] => US [patent_app_date] => 2014-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 28605 [patent_no_of_claims] => 66 [patent_no_of_ind_claims] => 48 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14888313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10857782 [patent_doc_number] => 08883983 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-11 [patent_title] => 'Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 14/261065 [patent_app_country] => US [patent_app_date] => 2014-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 163 [patent_no_of_words] => 73170 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14261065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10831574 [patent_doc_number] => 08859741 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-14 [patent_title] => 'Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 14/261087 [patent_app_country] => US [patent_app_date] => 2014-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 163 [patent_no_of_words] => 73179 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14261087 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10844735 [patent_doc_number] => 08871913 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-10-28 [patent_title] => 'Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 14/260975 [patent_app_country] => US [patent_app_date] => 2014-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 163 [patent_no_of_words] => 73180 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14260975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10864135 [patent_doc_number] => 08889834 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-18 [patent_title] => 'Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 14/260985 [patent_app_country] => US [patent_app_date] => 2014-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 163 [patent_no_of_words] => 73180 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14260985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9657552 [patent_doc_number] => 20140228557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-14 [patent_title] => 'ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 14/261063 [patent_app_country] => US [patent_app_date] => 2014-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 152 [patent_no_of_words] => 73156 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14261063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10939429 [patent_doc_number] => 20140342450 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-20 [patent_title] => 'ANTIBODIES TO CCR2' [patent_app_type] => utility [patent_app_number] => 14/244167 [patent_app_country] => US [patent_app_date] => 2014-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 37493 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14244167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13970501 [patent_doc_number] => 10214593 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-26 [patent_title] => Anti-idiotype antibody against anti-c-MET antibody [patent_app_type] => utility [patent_app_number] => 14/243751 [patent_app_country] => US [patent_app_date] => 2014-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 19063 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 834 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14243751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10932542 [patent_doc_number] => 20140335563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-11-13 [patent_title] => 'STABILIZED HUMAN IGG2 AND IGG3 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/228377 [patent_app_country] => US [patent_app_date] => 2014-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 19485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14228377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9849798 [patent_doc_number] => 08951523 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-02-10 [patent_title] => 'Targeting rare human PCSK9 variants for cholesterol treatment' [patent_app_type] => utility [patent_app_number] => 14/228760 [patent_app_country] => US [patent_app_date] => 2014-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 55717 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14228760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9602646 [patent_doc_number] => 20140199328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-17 [patent_title] => 'Interferon Alpha Antibodies And Their Uses' [patent_app_type] => utility [patent_app_number] => 14/222039 [patent_app_country] => US [patent_app_date] => 2014-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 30482 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14222039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10685873 [patent_doc_number] => 20160032014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9' [patent_app_type] => utility [patent_app_number] => 14/777401 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 53485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14777401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693799 [patent_doc_number] => 20160039945 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9' [patent_app_type] => utility [patent_app_number] => 14/777371 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38542 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14777371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14143109 [patent_doc_number] => 10251906 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-09 [patent_title] => Compositions and methods for inducing apoptosis [patent_app_type] => utility [patent_app_number] => 14/773791 [patent_app_country] => US [patent_app_date] => 2014-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 71 [patent_no_of_words] => 40371 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14773791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9560659 [patent_doc_number] => 20140178372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-26 [patent_title] => 'METHODS OF TREATING HEMATOLOGIC CANCERS' [patent_app_type] => utility [patent_app_number] => 14/190987 [patent_app_country] => US [patent_app_date] => 2014-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11586 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14190987 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9616161 [patent_doc_number] => 20140206018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-24 [patent_title] => 'ANTIBODIES AGAINST FATTY ACID SYNTHASE' [patent_app_type] => utility [patent_app_number] => 14/189288 [patent_app_country] => US [patent_app_date] => 2014-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13719 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14189288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10491247 [patent_doc_number] => 20150376268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS' [patent_app_type] => utility [patent_app_number] => 14/770160 [patent_app_country] => US [patent_app_date] => 2014-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 22481 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14770160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670345 [patent_doc_number] => 20140234209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'CHIMERIC AND HUMANIZED ANTI-HISTONE ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/180646 [patent_app_country] => US [patent_app_date] => 2014-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 36956 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14180646 [rel_patent_id] =>[rel_patent_doc_number] =>)